Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
UNIVERSITÄT LEIPZIG currently has 1 pending office actions within the Biotechnology & Pharmaceuticals technology area. This action is situated within 1 distinct art units, suggesting a concentrated area of research and patenting for the university. The prosecution is being handled by 1 distinct examiners, which limits the variety of examiner feedback the university must navigate. This structure provides a clear path for the current stage of patent acquisition.
The busiest examiner for this portfolio is PULLIAM, JOSEPH CONSTANTINE, who is responsible for 1 busiest examiner pending office action. As the total number of 1 pending office actions is limited, this examiner is the primary contact for the university's active prosecution. Practitioners should note that with 1 distinct examiners and 1 distinct art units, the strategy for the Biotechnology & Pharmaceuticals portfolio is highly focused. The outcome relies on effectively responding to the specific interpretations and requirements of this individual at the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PULLIAM, JOSEPH CONSTANTINE | 1 | 38.1% | +31.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17920109 | MULTI-GENE EXPRESSION ASSAY FOR PROSTATE CARCINOMA | PULLIAM, JOSEPH CONSTANTINE | 13d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17920109 | MULTI-GENE EXPRESSION ASSAY FOR PROSTATE CARCINOMA | PULLIAM, JOSEPH CONSTANTINE | 13d |
| Art Unit | Apps |
|---|---|
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17920109 | MULTI-GENE EXPRESSION ASSAY FOR PROSTATE CARCINOMA | PULLIAM, JOSEPH CONSTANTINE | 1687 | §101§112 | Final Rejection | 13d | Pending | May 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial